Baumgartner H, Boyle C M
Schweiz Med Wochenschr. 1982 Feb 20;112(8):281-5.
Diflunisal, a new analgesic/anti-inflammatory monosubstance, has been compared with naproxen in a double-blind study in patients with rheumatoid arthritis. In doses of 1 g diflunisal daily and 750 mg naproxen daily both therapies resulted in significant improvements in subjective and objective parameters measured - day and night pain, morning stiffness, Ritchie index, grip strength, and doctor and patient assessment of overall effect. Side effects were uncommon and of little significance in the diflunisal-treated patients, whereas two patients in the naproxen group were dropped from the study because of clinically significant drug-related side effects. It is concluded that diflunisal should be a very useful addition to the therapies currently available.
双氯芬酸，一种新型的镇痛/抗炎单物质，在一项针对类风湿性关节炎患者的双盲研究中与萘普生进行了比较。每日服用1克双氯芬酸和每日服用750毫克萘普生的两种治疗方法，在测量的主观和客观参数方面均有显著改善——白天和夜间疼痛、晨僵、里奇指数、握力以及医生和患者对总体疗效的评估。双氯芬酸治疗组的副作用不常见且影响不大，而萘普生组有两名患者因临床上与药物相关的显著副作用而退出研究。结论是双氯芬酸应是目前可用治疗方法中非常有用的补充药物。
